Skip to content

The Effectiveness of BreatheMAX Breathing Device on Secretion Clearance

The Effectiveness of BreatheMAX Breathing Device on Airway Secretion Clearance in Patients With Ventilatory Dependence

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01090804
Acronym
ESMOSC
Enrollment
14
Registered
2010-03-23
Start date
2009-08-31
Completion date
Unknown
Last updated
2010-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Disease

Keywords

BreatheMAX breathing device, Secretion clearance, Ventilatory dependence, Intubated patients

Brief summary

The purpose of this study is to determined effects of BreatheMAX on secretion clearance.

Interventions

secretion clearance, breathing exercise

Sponsors

Khon Kaen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
15 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* One sign of secretion accumulation in bronchi * Stable cardiopulmonary function * Good consciousness and good co-operation

Exclusion criteria

* Massive hemoptysis * Pneumothorax (untreated)

Design outcomes

Primary

MeasureTime frameDescription
secretion wet weight (gram)Three hours before, ten hours after treatment and night-time (02.00-07.00 am.)Airway mucus secretion was collected for three hours before and ten hours after treatment based on an auditory airway secretion sound and collected again at 02.00-07.00 am.The mucus secretion was collected by sterile suctioning technique via tracheostomy tube without adding any saline or sterile water.
viscosity of secretionThree hours before and after treatmentThe secretion were collected in three hours before and after treatment, It were measured viscosity by First The mucus was gently homogenized by tissue grinder 5 ml (Cw11-205, Cowie, UK) for six minute at 37 degree celsius Second using Micro-Oswald viscometers with a capillary diameter of 0.77 mm for viscosity measure at same temperature in each sample(before and after).

Secondary

MeasureTime frameDescription
Heart rate (beat/min)Before, during breathing exercise with device and immediate after treatmentHeart rate was monitored before, during and immediate after breathing exercise with BreatheMAX (6-10 beats/set, 10 set/day and rest between ste for 1 minute)
Oxygen saturation (%SpO2)Before, during breathing exercise with device and immediate after treatmentOxygen saturation was monitored before, during and immediate after breathing exercise with BreatheMAX (6-10 beats/set, 10 set/day and rest between set for 1 minute)
Respiratory rate (times/min)In rest interval between set (1 minute)Respiratory rate was measured by manual for 1 minute before, rest interval between set and immediate after breathing exercise with device (during the patients reconnection mechanical ventilation)

Countries

Thailand

Contacts

Primary ContactMiss Sujittra Kluayhomthong, Bachelor
rabbit_tigger@hotmail.com081-379-0647
Backup ContactMrs. Chulee Jones, Philosophy
Chujones46@yahoo.co.uk664-320-2399

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026